AIM ImmunoTech has completed enrollment for its Phase 2 DURIPANC trial ahead of schedule, with the final patient set for treatment in mid-June 2026, surpassing the original July target. The trial tests Ampligen combined with AstraZeneca’s Imfinzi for metastatic pancreatic cancer patients. This milestone keeps the company on track to evaluate the primary endpoint, Clinical Benefit Rate, by December 2026. Positive interim results and ongoing Phase 3 planning highlight Ampligen's potential as a new treatment for this deadly cancer with limited options.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
